Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95498

UPID:
VNN2_HUMAN

ALTERNATIVE NAMES:
Glycosylphosphatidyl inositol-anchored protein GPI-80; Protein FOAP-4; Vascular non-inflammatory molecule 2

ALTERNATIVE UPACC:
O95498; A0AUZ3; A6NDY1; A8K4E3; A8K7W0; B2DFZ0; B2DFZ1; B2DFZ2; B2DFZ3; F6XL73; Q2XUN1; Q9UJF3; Q9UMW2

BACKGROUND:
The enzyme Pantetheine hydrolase VNN2, recognized by its alternative names Glycosylphosphatidyl inositol-anchored protein GPI-80, Protein FOAP-4, and Vascular non-inflammatory molecule 2, is pivotal in recycling pantothenic acid (vitamin B5) through the specific hydrolysis of carboamide linkages in D-pantetheine, releasing cysteamine. It is also implicated in the thymus homing of bone marrow cells and may play a role in regulating beta-2 integrin-mediated cell adhesion, migration, and motility of neutrophil.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Pantetheine hydrolase VNN2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.